These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 3496960)
1. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma. Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960 [TBL] [Abstract][Full Text] [Related]
2. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins. Griffin T; Raso V Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454 [TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas. Griffin TW; Pagnini PG; McGrath JJ; McCann JC; Houston LL J Biol Response Mod; 1988 Dec; 7(6):559-67. PubMed ID: 3265147 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice. Marks A; Ettenson D; Bjorn MJ; Lei M; Baumal R Cancer Res; 1990 Jan; 50(2):288-92. PubMed ID: 2295069 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. FitzGerald DJ; Bjorn MJ; Ferris RJ; Winkelhake JL; Frankel AE; Hamilton TC; Ozols RF; Willingham MC; Pastan I Cancer Res; 1987 Mar; 47(5):1407-10. PubMed ID: 3493065 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
7. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Weil-Hillman G; Runge W; Jansen FK; Vallera DA Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451 [TBL] [Abstract][Full Text] [Related]
9. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins. Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079 [TBL] [Abstract][Full Text] [Related]
10. Potentiation of antitumor immunotoxins by liposomal monensin. Griffin T; Rybak ME; Recht L; Singh M; Salimi A; Raso V J Natl Cancer Inst; 1993 Feb; 85(4):292-8. PubMed ID: 8426373 [TBL] [Abstract][Full Text] [Related]
11. Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro. Recht LD; Griffin TW; Raso V; Salimi AR Cancer Res; 1990 Oct; 50(20):6696-700. PubMed ID: 2208135 [TBL] [Abstract][Full Text] [Related]
12. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors. Bjorn MJ; Groetsema G Cancer Res; 1987 Dec; 47(24 Pt 1):6639-45. PubMed ID: 3499979 [TBL] [Abstract][Full Text] [Related]
13. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284 [TBL] [Abstract][Full Text] [Related]
14. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Fulton RJ; Uhr JW; Vitetta ES Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547 [TBL] [Abstract][Full Text] [Related]
15. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin. Griffin TW; Pagnini PG; Houston LL J Biol Response Mod; 1987 Oct; 6(5):537-45. PubMed ID: 3500277 [TBL] [Abstract][Full Text] [Related]
17. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody. Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098 [TBL] [Abstract][Full Text] [Related]
18. Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin. Yokota S; Hara H; Luo Y; Seon BK Cancer Res; 1990 Jan; 50(1):32-7. PubMed ID: 2293557 [TBL] [Abstract][Full Text] [Related]
19. Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies. Griffin TW; Stocl M; Collins J; Fernandes J; Maher VE J Immunother (1991); 1992 Jan; 11(1):12-8. PubMed ID: 1734944 [TBL] [Abstract][Full Text] [Related]
20. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]